Minister of Innovative Development Ibrokhim Abdurahmonov had an online meeting with representatives of the Shanghai Institute of Matter Chinese Academy of Sciences, Xinjiang Institute of Physics and Chemical Technology, Sino-Uzbek Medical Technology Park, the ministerial press service reported.
During the meeting, information was given about the drug VV116 (“Remindevir”) against the COVID-19 virus, developed by the Shanghai Institute of Matter. Professor Shen Jingshan from the Shanghai Institute of Matter gave a presentation on the chemical and medical properties of this drug, during which they exchanged views on the effectiveness of the drug.
Remindevir, developed by Chinese scientists, is a new form of Remdesivir that is currently injectable, has low side effects. It will be available in pill form. Currently, the drug is undergoing clinical trials, and upon completion of the research, it is planned to manufacture it in the Navoi Free Economic Zone at a plant for the synthesis of pharmaceutical substances, which will be built in conjunction with the Shanghai Institute of Pharmacology.
“The pharmaceutical plant, the construction of which is planned in the Karmana district of Navoi region, will become the first enterprise in Uzbekistan that will carry out the chemical synthesis of drug substances. There are many talented chemists in Uzbekistan who have so far carried out the synthesis of substances only in the laboratories of research institutes, but the synthesis of these substances has not been brought to an industrial level. The creation of the plant will allow to receive capital from science, create new jobs, conditions for the production of competitive high-tech products,” Ibrokhim Abdurakhmonov, Minister of Innovative Development, said.
During the meeting, the parties exchanged views on accelerating the implementation of the project to create an Uzbek-Chinese medical technology park for the synthesis of medicines in the Navoi region.
